Current Oncology Reports

, 16:395 | Cite as

Advances in Therapy for Pediatric Sarcomas

  • Aaron Weiss
  • Jonathan Gill
  • John Goldberg
  • Joanne Lagmay
  • Holly Spraker-Perlman
  • Rajkumar Venkatramani
  • Damon Reed
Sarcomas (SR Patel, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Sarcomas

Abstract

Pediatric sarcomas are relatively rare malignancies individually. As a group they are typically approached with combination chemotherapies in addition to local control. Fortunately, these malignancies have been approached through careful clinical trial collaboration to define risk groups and appropriately deliver local control measures and systemic therapies. Although local disease is typically approached with curative intent, therapy typically lasts over 6 months and has significant associated morbidities. It is more difficult to cure metastatic disease or induce sustained remissions. In this article, we discuss recent advances in the understanding of the disease process and highlight recent and future cooperative group trials in osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, nonrhabdomyosarcoma soft tissue sarcomas, and desmoid tumor as well as discuss promising therapeutic approaches such as epigenetics and immunotherapy.

Keywords

Sarcomas Pediatric sarcomas Rare malignancies Oncology Therapy 

References

  1. 1.
    Ries LAG et al., editors. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. NIH publication no. 99-4649. Bethesda: National Cancer Institute; 1999.Google Scholar
  2. 2.
    Bleyer A et al., editors. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. NIH publication no. 06-5767. Bethesda: National Cancer Institute; 2006.Google Scholar
  3. 3.
    Bielack SS et al. Bone tumors in adolescents and young adults. Curr Treat Options in Oncol. 2008;9(1):67–80.Google Scholar
  4. 4.
    Federman N et al. The multidisciplinary management of osteosarcoma. Curr Treat Options in Oncol. 2009;10(1–2):82–93.Google Scholar
  5. 5.
    Kempf-Bielack B et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005;23(3):559–68.PubMedGoogle Scholar
  6. 6.
    Kager L et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21(10):2011–8.PubMedGoogle Scholar
  7. 7.
    Bielack SS et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776–90.PubMedGoogle Scholar
  8. 8.
    Ferrari S et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian sarcoma groups. J Clin Oncol. 2005;23(34):8845–52.PubMedGoogle Scholar
  9. 9.
    Meyers PA et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23(9):2004–11.PubMedGoogle Scholar
  10. 10.
    Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115(7):1531–43.PubMedCentralPubMedGoogle Scholar
  11. 11.
    Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006;6(7):1075–85.PubMedGoogle Scholar
  12. 12.
    Chen X et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 2014;7(1):104–12.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 2008;134(3):281–97.PubMedGoogle Scholar
  14. 14.
    Savage SA, Mirabello L. Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma. 2011;2011:548151.PubMedCentralPubMedGoogle Scholar
  15. 15.
    Sampson VB et al. A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. Front Oncol. 2013;3:132.PubMedCentralPubMedGoogle Scholar
  16. 16.
    Marina N et al. International collaboration is feasible in trials for rare conditions: the EURAMOS experience. Cancer Treat Res. 2009;152:339–53.PubMedGoogle Scholar
  17. 17.
    Bielack S et al. MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 "good response" randomization. J Clin Oncol. 2013;31(18 Suppl), LBA10504.Google Scholar
  18. 18.
    Ebb D et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. J Clin Oncol. 2012;30(20):2545–51.PubMedCentralPubMedGoogle Scholar
  19. 19.
    Chou AJ et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer. 2009;115(22):5339–48.PubMedCentralPubMedGoogle Scholar
  20. 20.
    Meyers PA et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children's Oncology Group. J Clin Oncol. 2008;26(4):633–8.PubMedGoogle Scholar
  21. 21.
    Goldsby RE et al. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Eur J Cancer. 2013;49(10):2384–91.PubMedCentralPubMedGoogle Scholar
  22. 22.
    Arndt CA et al. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group. Clin Cancer Res. 2010;16(15):4024–30.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Beaty 3rd O et al. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2010;55(3):440–5.PubMedGoogle Scholar
  24. 24.
    Bond M et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008;50(2):254–8.PubMedGoogle Scholar
  25. 25.
    Langevin AM et al. A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008;50(3):577–80.PubMedGoogle Scholar
  26. 26.
    Saylors 3rd RL et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19(15):3463–9.PubMedGoogle Scholar
  27. 27.
    Zwerdling T et al. Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group. Cancer. 2006;106(8):1821–8.PubMedGoogle Scholar
  28. 28.
    Jacobs S et al. Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group. Clin Cancer Res. 2010;16(2):750–4.PubMedCentralPubMedGoogle Scholar
  29. 29.
    Gorlick R et al. Children's Oncology Group's 2013 blueprint for research: bone tumors. Pediatr Blood Cancer. 2013;60(6):1009–15.PubMedGoogle Scholar
  30. 30.
    Chou AJ et al. Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. Pediatr Blood Cancer. 2012;60(4):580–6.PubMedGoogle Scholar
  31. 31.
    Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253–65.PubMedGoogle Scholar
  32. 32.
    Kolb EA et al. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013;60(8):1325–32.PubMedGoogle Scholar
  33. 33.
    Lamoureux F et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res. 2007;67(15):7308–18.PubMedGoogle Scholar
  34. 34.
    Mori K et al. Receptor activator of nuclear factor-κB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncol Rep. 2007;18(6):1365–71.PubMedGoogle Scholar
  35. 35.
    Heiner JP et al. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res. 1987;47(20):5377–81.PubMedGoogle Scholar
  36. 36.
    Roth M et al. Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer. 2014;120(4):548–54.PubMedGoogle Scholar
  37. 37.
    Maric G et al. Glycoprotein non-metastatic b (GPNMB): a metastatic mediator and emerging therapeutic target in cancer. Oncotargets Ther. 2013;6:839–52.Google Scholar
  38. 38.
    Esiashvili N, Goodman M, Marcus Jr RB. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J Pediatr Hematol Oncol. 2008;30(6):425–30.PubMedGoogle Scholar
  39. 39.
    Grier HE et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694–701.PubMedGoogle Scholar
  40. 40.
    Womer RB et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012;30(33):4148–54.PubMedCentralPubMedGoogle Scholar
  41. 41.
    Cotterill SJ et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000;18(17):3108–14.PubMedGoogle Scholar
  42. 42.
    Navid F et al. Second cancers in patients with the Ewing sarcoma family of tumours. Eur J Cancer. 2008;44(7):983–91.PubMedCentralPubMedGoogle Scholar
  43. 43.
    Erkizan HV et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med. 2009;15(7):750–6.PubMedCentralPubMedGoogle Scholar
  44. 44.
    Sankar S et al. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene. 2013;32(42):5089–100.PubMedCentralPubMedGoogle Scholar
  45. 45.
    Bennani-Baiti IM et al. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol. 2012;43(8):1300–7.PubMedGoogle Scholar
  46. 46.
    Grohar PJ et al. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst. 2011;103(12):962–78.PubMedCentralPubMedGoogle Scholar
  47. 47.
    Fong PC et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–34.PubMedGoogle Scholar
  48. 48.
    Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48.PubMedGoogle Scholar
  49. 49.
    Carrle D, Bielack S. Osteosarcoma lung metastases detection and principles of multimodal therapy. Cancer Treat Res. 2009;152:165–84.PubMedGoogle Scholar
  50. 50.
    Garnett MJ et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483(7391):570–5.PubMedCentralPubMedGoogle Scholar
  51. 51.
    Soldatenkov VA et al. Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factor. Oncogene. 1999;18(27):3954–62.PubMedGoogle Scholar
  52. 52.
    Olmos D et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol. 2010;11(2):129–35.PubMedCentralPubMedGoogle Scholar
  53. 53.
    Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer. 2012;59(1):5–10.PubMedCentralPubMedGoogle Scholar
  54. 54.
    Juergens H et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol. 2011;29(34):4534–40.PubMedCentralPubMedGoogle Scholar
  55. 55.
    Pappo AS et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research Through Collaboration study. J Clin Oncol. 2011;29(34):4541–7.PubMedCentralPubMedGoogle Scholar
  56. 56.
    Anderson JL et al. Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities. Pediatr Res. 2012;72(2):112–21.PubMedGoogle Scholar
  57. 57.
    O'Reilly KE et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66(3):1500–8.PubMedCentralPubMedGoogle Scholar
  58. 58.
    Schwartz GK et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013;14(4):371–82.PubMedCentralPubMedGoogle Scholar
  59. 59.
    Naing A et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res. 2012;18(9):2625–31.PubMedGoogle Scholar
  60. 60.
    Ferrari A et al. Soft tissue sarcoma across the age spectrum: a population-based study from the surveillance epidemiology and end results database. Pediatr Blood Cancer. 2011;57(6):943–9.PubMedGoogle Scholar
  61. 61.
    Perez EA et al. Rhabdomyosarcoma in children: a SEER population based study. J Surg Res. 2011;170(2):e243–51.PubMedGoogle Scholar
  62. 62.
    Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene. 2001;20(40):5736–46.PubMedGoogle Scholar
  63. 63.
    Williamson D et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol. 2010;28(13):2151–8.PubMedGoogle Scholar
  64. 64.
    Skapek SX et al. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a Children's Oncology Group report. Pediatr Blood Cancer. 2013;60(9):1411–7.PubMedGoogle Scholar
  65. 65.
    Pappo AS et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J Clin Oncol. 2007;25(4):362–9.PubMedGoogle Scholar
  66. 66.
    Children's Oncology Group Fall Meeting. 2013. Dallas.Google Scholar
  67. 67.
    Weigel B et al. Early results from Children's Oncology Group (COG) ARST0431: intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS). J Clin Oncol. 2010;28(15 Suppl):9503.Google Scholar
  68. 68.
    Shern JF et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014;4(2):216–31.PubMedGoogle Scholar
  69. 69.
    Shukla N et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res. 2012;18(3):748–57.PubMedCentralPubMedGoogle Scholar
  70. 70.
    Li SQ et al. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). PLoS One. 2013;8(10):e76551.PubMedCentralPubMedGoogle Scholar
  71. 71.
    Gerber HP et al. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 2000;60(22):6253–8.PubMedGoogle Scholar
  72. 72.
    Dilling MB et al. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res. 1994;54(4):903–7.PubMedGoogle Scholar
  73. 73.
    Houghton PJ et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2008;50(4):799–805.PubMedGoogle Scholar
  74. 74.
    Kolb EA et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2008;50(6):1190–7.PubMedGoogle Scholar
  75. 75.
    Ferrari A et al. Adult-type soft tissue sarcomas in pediatric-age patients: experience at the Istituto Nazionale Tumori in Milan. J Clin Oncol. 2005;23(18):4021–30.PubMedGoogle Scholar
  76. 76.
    Spunt SL et al. Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children's Research Hospital. J Clin Oncol. 1999;17(12):3697–705.PubMedGoogle Scholar
  77. 77.
    Blaes AH et al. Pathologic femur fractures after limb-sparing treatment of soft-tissue sarcomas. J Cancer Surviv. 2010;4(4):399–404.PubMedGoogle Scholar
  78. 78.
    Tukenova M et al. Radiation therapy and late mortality from second sarcoma, carcinoma, and hematological malignancies after a solid cancer in childhood. Int J Radiat Oncol Biol Phys. 2011;80(2):339–46.PubMedGoogle Scholar
  79. 79.
    Pervaiz N et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.PubMedGoogle Scholar
  80. 80.
    Pappo AS et al. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group study. J Clin Oncol. 2005;23(18):4031–8.PubMedGoogle Scholar
  81. 81.
    Pratt CB et al. Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group study. Med Pediatr Oncol. 1998;30(4):201–9.PubMedGoogle Scholar
  82. 82.
    Demetri GD et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–38.PubMedGoogle Scholar
  83. 83.
    Gooskens SL et al. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP). Pediatr Blood Cancer. 2010;55(2):369–73.PubMedGoogle Scholar
  84. 84.
    Heinrich MC et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21(23):4342–9.PubMedGoogle Scholar
  85. 85.
    McArthur GA et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium study B2225. J Clin Oncol. 2005;23(4):866–73.PubMedGoogle Scholar
  86. 86.
    Kadoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell. 2013;153(1):71–85.PubMedCentralPubMedGoogle Scholar
  87. 87.
    Barretina J et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010;42(8):715–21.PubMedCentralPubMedGoogle Scholar
  88. 88.
    Thomas RK et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39(3):347–51.PubMedGoogle Scholar
  89. 89.
    Wardelmann E et al. Soft tissue sarcoma: from molecular diagnosis to selection of treatment. Pathological diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies. Ann Oncol. 2010;21 Suppl 7:265–9.Google Scholar
  90. 90.
    Holtkamp N et al. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis. 2006;27(3):664–71.PubMedGoogle Scholar
  91. 91.
    Park MS, Ravi V, Araujo DM. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol. 2010;22(4):351–5.PubMedGoogle Scholar
  92. 92.
    Potti A et al. Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. J Cancer Res Clin Oncol. 2004;130(1):52–6.PubMedGoogle Scholar
  93. 93.
    Tamborini E et al. Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma. Clin Cancer Res. 2004;10(3):938–43.PubMedGoogle Scholar
  94. 94.
    Hurwitz HI et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15(12):4220–7.PubMedGoogle Scholar
  95. 95.
    Sleijfer S et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126–32.PubMedGoogle Scholar
  96. 96.
    van der Graaf WT et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86.PubMedGoogle Scholar
  97. 97.
    Glade Bender JL et al. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a Children’s Oncology Group Phase I Consortium report. J Clin Oncol. 2013;31(24):3034–43.PubMedCentralPubMedGoogle Scholar
  98. 98.
    Abou-Alfa GK, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 304(19):2154-60.Google Scholar
  99. 99.
    Wu YL et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013;14(8):777–86.PubMedGoogle Scholar
  100. 100.
    Eilber FC et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol. 2001;19(13):3203–9.PubMedGoogle Scholar
  101. 101.
    Alebouyeh M et al. Aggressive intra-abdominal fibromatosis in children and response to chemotherapy. Pediatr Hematol Oncol. 2005;22(6):447–51.PubMedGoogle Scholar
  102. 102.
    Reitamo JJ, Scheinin TM, Hayry P. The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am J Surg. 1986;151(2):230–7.PubMedGoogle Scholar
  103. 103.
    Bertario L et al. Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer. 2001;95(2):102–7.PubMedGoogle Scholar
  104. 104.
    Gomez Garcia EB, Knoers NV. Gardner's syndrome (familial adenomatous polyposis): a cilia-related disorder. Lancet Oncol. 2009;10(7):727–35.PubMedGoogle Scholar
  105. 105.
    Pressey JG et al. Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. Pediatr Blood Cancer. 2010;54(7):1035–7.PubMedGoogle Scholar
  106. 106.
    Buitendijk S et al. Pediatric aggressive fibromatosis: a retrospective analysis of 13 patients and review of literature. Cancer. 2005;104(5):1090–9.PubMedGoogle Scholar
  107. 107.
    Faulkner LB et al. Pediatric desmoid tumor: retrospective analysis of 63 cases. J Clin Oncol. 1995;13(11):2813–8.PubMedGoogle Scholar
  108. 108.
    Melis M, Zager JS, Sondak VK. Multimodality management of desmoid tumors: how important is a negative surgical margin? J Surg Oncol. 2008;98(8):594–602.PubMedGoogle Scholar
  109. 109.
    Jabbari S et al. Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy. Int J Radiat Oncol Biol Phys. 2009;75(1):177–82.PubMedGoogle Scholar
  110. 110.
    Merchant TE et al. Long-term results with radiation therapy for pediatric desmoid tumors. Int J Radiat Oncol Biol Phys. 2000;47(5):1267–71.PubMedGoogle Scholar
  111. 111.
    Ayala AG et al. Desmoid fibromatosis: a clinicopathologic study of 25 children. Semin Diagn Pathol. 1986;3(2):138–50.PubMedGoogle Scholar
  112. 112.
    Constantinidou A et al. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009;45(17):2930–4.PubMedGoogle Scholar
  113. 113.
    Heinrich MC et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol. 2006;24(7):1195–203.PubMedGoogle Scholar
  114. 114.
    Meazza C et al. Aggressive fibromatosis in children and adolescents: the Italian experience. Cancer. 2010;116(1):233–40.PubMedGoogle Scholar
  115. 115.
    Raney B et al. Nonsurgical management of children with recurrent or unresectable fibromatosis. Pediatrics. 1987;79(3):394–8.PubMedGoogle Scholar
  116. 116.
    Skapek SX et al. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group phase II trial. J Clin Oncol. 2007;25(5):501–6.PubMedGoogle Scholar
  117. 117.
    Skapek SX et al. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study. Pediatr Blood Cancer. 2013;60(7):1108–12.PubMedGoogle Scholar
  118. 118.
    Fiore M et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16(9):2587–93.PubMedGoogle Scholar
  119. 119.
    Gronchi A et al. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm—a position paper from the Italian and the French sarcoma group. Ann Oncol. 2014;25(3):578–83.PubMedGoogle Scholar
  120. 120.
    Lazar AJ et al. Specific mutations in the β-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173(5):1518–27.PubMedCentralPubMedGoogle Scholar
  121. 121.
    Tejpar S et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene. 1999;18(47):6615–20.PubMedGoogle Scholar
  122. 122.
    Goldberg JM. Immunotherapy of sarcomas. Curr Opin Oncol. 2013;25(4):390–7.PubMedGoogle Scholar
  123. 123.
    Strbo N, Podack ER. Secreted heat shock protein gp96-Ig: an innovative vaccine approach. Am J Reprod Immunol. 2008;59(5):407–16.PubMedGoogle Scholar
  124. 124.
    Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.PubMedCentralPubMedGoogle Scholar
  125. 125.
    Brinkrolf P et al. A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease. Int J Cancer. 2009;125(4):879–86.PubMedGoogle Scholar
  126. 126.
    Salama AK, Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res. 2011;17(14):4622–8.PubMedGoogle Scholar
  127. 127.
    Topalian SL et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.PubMedCentralPubMedGoogle Scholar
  128. 128.
    Maki RG et al. A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma. 2013;2013:168145.PubMedCentralPubMedGoogle Scholar
  129. 129.
    Robbins PF et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917–24.PubMedCentralPubMedGoogle Scholar
  130. 130.
    Mackall CL et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res. 2008;14(15):4850–8.PubMedCentralPubMedGoogle Scholar
  131. 131.
    Burdach S et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-cell transplant programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol. 2000;11(11):1451–62.PubMedGoogle Scholar
  132. 132.
    Gore L et al. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res. 2008;14(14):4517–25.PubMedCentralPubMedGoogle Scholar
  133. 133.
    Berghuis D et al. Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis. Clin Sarcoma Res. 2012;2(1):8.PubMedCentralPubMedGoogle Scholar
  134. 134.
    Rao-Bindal K et al. The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases. Curr Cancer Drug Targets. 2013;13(4):411–22.PubMedCentralPubMedGoogle Scholar
  135. 135.
    Keshelava N et al. Initial testing (stage 1) of vorinostat (SAHA) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2009;53(3):505–8.PubMedCentralPubMedGoogle Scholar
  136. 136.
    Krishnadas DK et al. Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1. Tumor Biol. 2014. doi:10.1007/s13277-014-1764-9.Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Aaron Weiss
    • 1
  • Jonathan Gill
    • 2
  • John Goldberg
    • 3
  • Joanne Lagmay
    • 4
  • Holly Spraker-Perlman
    • 5
  • Rajkumar Venkatramani
    • 6
  • Damon Reed
    • 7
  1. 1.Division of Pediatric Hematology-OncologyMaine Medical CenterPortlandUSA
  2. 2.Children’s Hospital at MontefioreAlbert Einstein College of MedicineBronxUSA
  3. 3.Department of PediatricsUniversity of Miami Miller School of MedicineMiamiUSA
  4. 4.Division of Pediatric Hematology/Oncology, Department of PediatricsUniversity of FloridaGainesvilleUSA
  5. 5.Division of Pediatric Oncology, Primary Children’s HospitalUniversity of UtahSalt Lake CityUSA
  6. 6.Division of Hematology, Oncology & BMT, Children’s Hospital Los AngelesUniversity of Southern CaliforniaLos AngelesUSA
  7. 7.Sarcoma Department, Adolescent and Young Adult ProgramChemical Biology and Molecular Medicine, Moffitt Cancer CenterTampaUSA

Personalised recommendations